Brii Biosciences Limited (2137) AI Stock Analysis

• Market Cap: HK$1.47B
• Dividend Yield: N/A
• Average Volume (3M): 5.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: -100.00%
• EPS Growth: -176.44%
• Country: HK
• Employees: 98
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 732,058,500
• 10 Day Avg. Volume: 10,833,565
• 30 Day Avg. Volume: 5,593,990
• PEG Ratio: 0.03
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: HK$2.00 ▼(-0.50%Downside)

The stock score is primarily impacted by financial performance challenges, including negative cash flow and profitability issues. Technical analysis provides some positive momentum, but valuation metrics highlight concerns with negative earnings. The absence of earnings call and corporate events data limits further insights.

Brii Biosciences Limited Business Overview & Revenue Model

Company Description

Brii Biosciences Limited (2137) is a biotechnology company focused on developing innovative therapies for infectious diseases and other significant health challenges. The company engages in the research, development, and commercialization of medicines to address unmet medical needs. Its core products revolve around infectious diseases such as hepatitis B virus (HBV) and HIV, leveraging partnerships and cutting-edge science to bring new solutions to market.

How the Company Makes Money

Brii Biosciences Limited generates revenue through the development and commercialization of pharmaceutical products aimed at treating infectious diseases. The company's revenue model includes licensing agreements, collaborative research and development partnerships, and milestone payments from its strategic partners. These collaborations often involve sharing the costs and risks associated with drug development, while enabling Brii Biosciences to receive royalties from the sales of successfully commercialized products. Additionally, the company may benefit from government grants and funding for research into infectious disease treatments, contributing to its overall earnings.

Brii Biosciences Limited Financial Statement Overview

Summary

Brii Biosciences shows a strong equity position with substantial cash reserves, but faces severe profitability and cash flow challenges. The net loss widened in 2024, and the company struggles with negative free cash flow and operational inefficiencies, highlighting potential financial instability.

Income Statement

Brii Biosciences has experienced fluctuating revenue trends with a decline from 2023 to 2024. The net loss widened significantly in 2024, indicating profitability challenges. Margins such as the Gross Profit Margin remain stable at 100%, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company's balance sheet shows a strong equity position but also reveals a concerning debt-to-equity ratio due to negative equity in previous years. The equity ratio is favorable, indicating a well-capitalized company, though historical liabilities have been significant relative to assets.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which suggests challenges in generating cash from operations. The lack of operating cash flow in 2024 highlights potential liquidity risks, though substantial cash reserves provide a buffer.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.29M	56.32M	51.63M	92.54M	82.22M
Gross Profit	54.29M	56.32M	51.63M	92.54M	82.22M
EBITDA	-392.51M	-168.20M	-503.58M	-602.80M	-890.79M
Net Income	-508.16M	-174.83M	-452.63M	-4.12B	-1.21B
Balance Sheet
Total Assets	2.71B	3.20B	3.39B	3.61B	1.27B
Cash, Cash Equivalents and Short-Term Investments	2.33B	2.66B	3.00B	3.35B	1.05B
Total Debt	28.02M	3.16M	12.66M	21.62M	28.33M
Total Liabilities	100.55M	125.87M	234.35M	300.44M	3.01B
Stockholders Equity	2.66B	3.12B	3.19B	3.34B	-1.74B
Cash Flow
Free Cash Flow	-376.12M	-643.62M	-635.57M	-880.49M	-403.72M
Operating Cash Flow	-372.89M	-594.01M	-496.28M	-879.46M	-403.72M
Investing Cash Flow	895.47M	-104.35M	-1.43B	-475.76M	-43.65M
Financing Cash Flow	-9.41M	-10.98M	-3.04M	3.23B	657.00M

Brii Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Positive. The current price of 2.01 is above the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.86, and above the 200-day MA of 1.56, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.35 is Neutral, neither overbought nor oversold. The STOCH value of 42.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2137.

Brii Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	71 Outperform	HK$2.13B	53.00	4.92%	―	38.48%	―
Sector *	61 Neutral	HK$17.40B	5.81	-7.44%	3.53%	11.55%	-28.15%
2126	59 Neutral	HK$2.16B	―	-41.34%	―	-10.78%	24.88%
1244	57 Neutral	HK$1.89B	―	-21.22%	―	-31.34%	67.95%
6998	51 Neutral	HK$1.43B	―	-4.30%	―	―	92.45%
2137	49 Neutral	HK$1.47B	―	-17.41%	―	-100.00%	-176.44%
2511	36 Underperform	HK$1.88B	―	-67.57%	―	―	54.79%

Brii Biosciences Limited Corporate Events

Brii Biosciences Partners with Joincare for BRII-693 Development in Greater China

Brii Biosciences Limited has entered into a licensing agreement with Joincare Pharmaceutical Group to develop and commercialize BRII-693, a novel antibiotic for multidrug-resistant infections, in Greater China. This partnership leverages Joincare’s expertise in manufacturing and commercialization, aiming to address the critical unmet clinical needs for hospital antibiotics in the region, thereby enhancing Brii Biosciences’ strategic positioning in the anti-infection market.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Announces AGM Results and Board Changes

Brii Biosciences Limited announced the results of its Annual General Meeting held on June 3, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements, re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors, which underscores the company’s stability and ongoing commitment to strong governance practices.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Reports Promising Phase 2 Results for HBV Treatment

Brii Biosciences Limited announced promising interim data from its Phase 2 ENSURE study, presented at the European Association for the Study of the Liver Congress 2025. The study evaluates the combination of elebsiran, an investigational siRNA, with pegylated interferon alpha (PEG-IFN α) in treating chronic hepatitis B virus (HBV) infection. Results showed that participants previously treated with BRII-179, a therapeutic vaccine, achieved faster and higher rates of hepatitis B surface antigen (HBsAg) seroclearance compared to those without prior treatment. This suggests that pre-treatment with BRII-179 may enhance immune response, potentially allowing for shorter treatment durations. The findings could significantly impact the treatment landscape for chronic HBV, offering a more effective and efficient therapeutic option for patients.